Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

被引：0
|
作者：
Jennypher Mudunuru
Chen Ren
David R. Taft
Manoj Maniar
机构：
[1] Long Island University,Division of Pharmaceutical Sciences
[2] Onconova Therapeutics,undefined
[3] Inc.,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：531 / 538
页数：7
相关论文
共 50 条
  • [31] The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
    Laura Morrison
    Sibylle Loibl
    Nicholas C. Turner
    Nature Reviews Clinical Oncology, 2024, 21 : 89 - 105
  • [32] The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment
    Morrison, Laura
    Loibl, Sibylle
    Turner, Nicholas C.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (02) : 89 - 105
  • [33] Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
    Liu, Yan-ping
    Hu, Ming-hui
    Lin, Ping-ping
    Li, Ting
    Liu, Shu-qin
    Wang, Yu-ya
    Li, Shao-rong
    Li, Xiang-kun
    Wang, Chen-jing
    Cao, Yu
    DRUGS IN R&D, 2022, 22 (02) : 175 - 182
  • [34] Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
    Yan-ping Liu
    Ming-hui Hu
    Ping-ping Lin
    Ting Li
    Shu-qin Liu
    Yu-ya Wang
    Shao-rong Li
    Xiang-kun Li
    Chen-jing Wang
    Yu Cao
    Drugs in R&D, 2022, 22 : 175 - 182
  • [35] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [36] MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
    de Leeuw, Renee
    McNair, Christopher
    Schiewer, Matthew J.
    Neupane, Neermala Poudel
    Brand, Lucas J.
    Augello, Michael A.
    Li, Zhen
    Cheng, Larry C.
    Yoshida, Akihiro
    Courtney, Sean M.
    Hazard, E. Starr
    Hardiman, Gary
    Hussain, Maha H.
    Diehl, J. Alan
    Drake, Justin M.
    Kelly, Wm. Kevin
    Knudsen, Karen E.
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4201 - 4214
  • [37] Preclinical evaluation of CDK4/6 inhibitor and biomarker exploration in gastric cancer
    Bae, Hyun Joo
    Kwon, Woo Sun
    Kim, Hyun Jeong
    Kang, Sun Kyoung
    Jeong, Inhye
    Kim, Tae Soo
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
    Morrison, Chris
    NATURE BIOTECHNOLOGY, 2015, 33 (04) : 323 - 324
  • [39] Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment
    Liu, Minghui
    Liu, Hongyu
    Chen, Jun
    ONCOLOGY REPORTS, 2018, 39 (03) : 901 - 911
  • [40] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
12345